Duet Series A 2026: $15M for NP-Owned Clinics

Lead

Duet, a New York-based startup that aggregates independent nurse practitioner (NP) primary care practices, announced a $15M Series A on November 12, 2026. Kairos led the round, and existing backer Lerer Hippeau took part. The company did not disclose a valuation.

The raise brings Duet's total capital to $22.5M. Founder and CEO Jonathan Goldberg, a former Knotel executive, started the company in 2023. Duet says it will use the money to bring more clinics into the network, deepen value-based contracts with insurers and expand its engineering team to build more automation tools.

What Does Duet Actually Do?

Duet works as a back-office and contracting layer for nurse practitioners who own their practices. It handles billing, credentialing and payer contracting, and supplies predictive clinical software. The practices stay independently owned.

The network now covers more than 130 clinics across 21 states and about 150,000 patients, with roughly 400,000 visits a year. Many of those patients live in rural and underserved communities. Duet's named payer partners are Anthem, Cigna, Centene and Molina.

How Does Duet Make Money?

Duet earns revenue from shared savings and quality incentives under value-based contracts, and it absorbs downside financial risk when those contracts underperform. The company says it manages about $100M in patient medical spend under such arrangements.

That structure matters more than the clinic count. Small practices rarely win enterprise contracts from large insurers on their own, so pooling them gives each clinic access to terms it could not negotiate alone. It also means Duet's income depends on keeping medical costs down, not on visit volume.

Why Is a Medicare ACO the Next Step?

An Accountable Care Organization lets groups of providers share in Medicare savings when they hold down costs and meet quality targets. Duet plans to launch what it calls the first NP-led Medicare ACO in 2027, governed by nurse practitioners.

The ACO would give independent practices a route into federal shared savings programs without selling to a hospital system or a larger physician group. Duet has not said how many clinics will join at launch or what financial reserves the ACO will need. Medicare ACOs carry real downside risk in their more advanced tracks, and a young company adding that exposure on top of commercial contracts will face scrutiny.

What Results Does Duet Report?

The company's own figures point to lower acute-care use and better screening. Duet reports a 20% reduction in emergency room utilization and a 30% increase in preventive cancer screening. It says 25% of previously lapsed patients re-engaged with care, and its patient Net Promoter Score is 92.

On the practice side, Duet says clinic revenue rose 25% to 50% after joining. In New Hampshire, it reports total cost of care 19% below benchmark. These are company-reported numbers, not independently audited, and the comparison baselines were not specified.

What Does the Round Say About Primary Care Investing?

A $15M Series A is modest next to the nine-figure rounds that primary care companies raised in the earlier venture cycle. Investors then funded owned-clinic models that built or bought sites at heavy cost, and several of those companies struggled with the economics of risk-bearing care.

Duet's asset-light approach avoids buying clinics, since practitioners own them. The round's size fits that model, with capital going mainly to software and contracting rather than real estate. The open question is whether Duet can keep absorbing downside risk as the dollars under management grow beyond the current $100M.

Outlook

Duet enters 2027 with $22.5M raised, more than 130 clinics and a plan to put nurse practitioners at the head of a Medicare ACO. The test will be whether its reported savings hold as the network widens into new states and into Medicare's risk-bearing structure. Valuation, ACO membership and reserve requirements remain undisclosed.